| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.24 | 4e-06 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | 0.16 | 5e-06 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.23 | 2e-05 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.24 | 3e-05 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.21 | 6e-05 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.14 | 8e-05 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.22 | 0.0001 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0001 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |